Patient Reported Outcomes (PRO) among Patients Receiving Home Hemodialysis (HHD) with the Tablo® Hemodialysis System.

Wazny JH1, Holmes CD1, D’Alessandri-Silva C1, Chertow GM2

Study Overview
- Prospective, multicenter, observational study of patients with ESRD utilizing Tablo Hemodialysis System, for Home HD.
- Goal: Report on first 57 patients enrolled onto the HOME Registry.
- N=57, reporting at 1, 3, 6, 9, and 12 months post-home dialysis initiation.
- Age (yr)-56, Male ~67%, w/ 60% of subjects receiving an AV Fistula.

Key Results
- 45% patients enrolled transitioned from in-center dialysis.
- SF-12 PHC and ISI had positive correlations with time, at p=0.046 and p=0.0035, respectively. Every 1 month increase in time was associated with a 0.417 increase in the SF-12 PHC and a 0.272 decrease in ISI score.
- There was no significant relation between time and the SF-12 MHC (p=0.19).

Conclusion
- Preliminary results show favorable effects of Tablo-enabled HHD on self-reported physical health and symptoms of insomnia.

Figure 1: ISI, SF-12 PHC & MHC Trend over 12 months on HHD